These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 25743139)
1. [Effect of tolvaptan on ascites due to malignancy]. Mitsuhashi N; Nemoto S; Satoh Y; Aoki Y; Teranaka R; Sasaki K; Shimazaki R; Ueda A; Nishino H; Akiyama T; Hosokawa I; Yoichi T; Kawamoto J; Kuboki S; Yoshitomi H; Kato A; Shimizu Y; Ohtsuka M; Shimizu H; Miyazaki M Gan To Kagaku Ryoho; 2015 Feb; 42(2):201-5. PubMed ID: 25743139 [TBL] [Abstract][Full Text] [Related]
2. Tolvaptan for the treatment of liver cirrhosis oedema. Sakaida I Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):461-70. PubMed ID: 24678622 [TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. Zhang X; Wang SZ; Zheng JF; Zhao WM; Li P; Fan CL; Li B; Dong PL; Li L; Ding HG World J Gastroenterol; 2014 Aug; 20(32):11400-5. PubMed ID: 25170228 [TBL] [Abstract][Full Text] [Related]
4. Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis. Chishina H; Hagiwara S; Nishida N; Ueshima K; Sakurai T; Ida H; Minami Y; Takita M; Kono M; Minami T; Iwanishi M; Umehara Y; Watanabe T; Komeda Y; Arizumi T; Kudo M Dig Dis; 2016; 34(6):659-664. PubMed ID: 27750234 [TBL] [Abstract][Full Text] [Related]
5. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. Komiyama Y; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Yasui Y; Tamaki N; Takada H; Higuchi M; Gotou T; Kubota Y; Takaura K; Hayashi T; Oh W; Okada M; Enomoto N; Izumi N PLoS One; 2017; 12(3):e0174649. PubMed ID: 28362879 [TBL] [Abstract][Full Text] [Related]
6. Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites. Goto A; Terai S; Nakamura M; Matsumoto M; Sakaida I Clin J Gastroenterol; 2015 Feb; 8(1):47-51. PubMed ID: 25475138 [TBL] [Abstract][Full Text] [Related]
7. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis. Tajiri K; Tokimitsu Y; Ito H; Atarashi Y; Kawai K; Minemura M; Yasumura S; Takahara T; Shimizu Y; Sugiyama T Dig Dis; 2018; 36(4):314-321. PubMed ID: 29852495 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study. Uojima H; Hidaka H; Nakayama T; Sung JH; Ichita C; Tokoro S; Masuda S; Sasaki A; Koizumi K; Egashira H; Kako M World J Gastroenterol; 2017 Dec; 23(45):8062-8072. PubMed ID: 29259382 [TBL] [Abstract][Full Text] [Related]
9. Cases with Refractory Ascites and a Delayed Response to Tolvaptan. Hagiwara S; Nishida N; Chishina H; Ida H; Sakurai T; Komeda Y; Kitano M; Kudo M Intern Med; 2016; 55(22):3273-3277. PubMed ID: 27853068 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. Miyazaki M; Yada M; Tanaka K; Senjyu T; Goya T; Motomura K; Kohjima M; Kato M; Masumoto A; Kotoh K World J Gastroenterol; 2017 Aug; 23(29):5379-5385. PubMed ID: 28839438 [TBL] [Abstract][Full Text] [Related]
11. Curative Effect and Safety of Tolvaptan Combined With Traditional Diuretics in Treatment of Patients With Cirrhotic Ascites and Relevant Research on Its Dose. Li X; Liu S; Xu H; Zhou W Am J Ther; 2023 Mar-Apr 01; 30(2):158-162. PubMed ID: 33416254 [No Abstract] [Full Text] [Related]
12. Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial. Wang YF; Tang JT; Han T; Ding HG; Ye WJ; Wang MR; Cheng J; Yang YP; Chen CW; Xie Q; Mao Q; Niu JQ; Wang ZH; Wei Z; Chen YX; Zeng M; Mao YM J Dig Dis; 2018 Mar; 19(3):144-154. PubMed ID: 29389068 [TBL] [Abstract][Full Text] [Related]
13. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of tolvaptan in patients hospitalized for heart failure with refractory hyponatremia. Clinical experience in daily practice. Salterain-Gonzalez N; Esteban-Fernández A; García-López M; Lavilla-Royo FJ; Gavira-Gómez JJ Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):503-4. PubMed ID: 24776057 [No Abstract] [Full Text] [Related]
15. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia. Wang S; Zhang X; Han T; Xie W; Li Y; Ma H; Liebe R; Weng H; Ding HG BMC Gastroenterol; 2018 Sep; 18(1):137. PubMed ID: 30180806 [TBL] [Abstract][Full Text] [Related]
16. [Management of ascites in cirrhotic patients]. Kurosaki M; Nakanishi H; Izumi N Nihon Shokakibyo Gakkai Zasshi; 2017; 114(1):27-34. PubMed ID: 28070092 [No Abstract] [Full Text] [Related]
17. Use of tolvaptan in patients with hyponatremia due to heart failure: initial experience. Rodríguez-de Muñoz YM; Sánchez-Lázaro IJ; Almenar-Bonet L; Martínez-Dolz L; Rodríguez-Serrano M; Salvador-Sanz A Rev Esp Cardiol (Engl Ed); 2013 Apr; 66(4):319-21. PubMed ID: 24775629 [No Abstract] [Full Text] [Related]
18. Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis. Sakaida I; Terai S; Nakajima K; Shibasaki Y; Tachikawa S; Tsubouchi H J Gastroenterol; 2017 Feb; 52(2):229-236. PubMed ID: 27379386 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. Sakaida I; Yamashita S; Kobayashi T; Komatsu M; Sakai T; Komorizono Y; Okada M; Okita K; J Int Med Res; 2013 Jun; 41(3):835-47. PubMed ID: 23685892 [TBL] [Abstract][Full Text] [Related]
20. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. Namba M; Hiramatsu A; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Tsuge M; Imamura M; Chayama K J Gastroenterol; 2020 Feb; 55(2):217-226. PubMed ID: 31485782 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]